Stock Events

Stock Events

Oculis 

$12.97
20
+$0.01+0.08% Wednesday 20:00
+$0.00+0%Wednesday 20:00After hours

Statistics

Day High
12.99
Day Low
12.95
52W High
34.48
52W Low
10.52
Volume
7,951
Avg. Volume
-
Mkt Cap
720.2M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

5NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-0.78
-0.59
-0.39
-0.2
Expected EPS
-0.5007828972
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2023
2024
2025
0Revenue
-120.39MNet Income

Analyst Ratings

34.50Average Price Target
The highest estimate is 45.00.
From 6 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow OCS. It's not an investment recommendation.
Microsoft
5
MSFT
NVIDIA
5
NVDA
Apple
4
AAPL
Meta Platforms
4
META

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Regeneron Pharmaceuticals
REGN
Mkt Cap85.87B
Regeneron Pharmaceuticals competes with Oculis in the ophthalmology space, particularly in treatments for eye diseases like age-related macular degeneration.
Novartis
NVS
Mkt Cap301.95B
Novartis is a major player in the development of drugs for eye conditions, directly competing with Oculis in the ophthalmic drug market.
Abbvie
ABBV
Mkt Cap468.22B
AbbVie, through its acquisition of Allergan, has a strong presence in the eye care market, especially in treatments for conditions like dry eye, directly competing with Oculis.
Regenxbio
RGNX
Mkt Cap707.66M
REGENXBIO is involved in gene therapy for ocular diseases, offering innovative treatments that compete with Oculis's drug development efforts.
Bausch Health Companies
BHC
Mkt Cap2.41B
Bausch Health Companies, through its eye health division, competes in the same space as Oculis, particularly in treatments for eye diseases.
Rogers
ROG
Mkt Cap2.26B
Roche, with its ophthalmology division, competes in developing treatments for eye diseases, including macular degeneration and diabetic retinopathy, areas Oculis is also targeting.
GSK
GSK
Mkt Cap104.97B
GlaxoSmithKline has initiatives in developing treatments for eye conditions, potentially competing with Oculis in the broader ophthalmology market.
Astrazeneca
AZN
Mkt Cap257.42B
AstraZeneca, through its acquisition of Alexion Pharmaceuticals, competes in the space of treatments for diseases including those affecting the eye, aligning as a competitor to Oculis.

About

Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company has locations in five countries: Switzerland, Iceland, France, U.S. and Hong Kong.
Show more...
CEO
Riad Sherif
Employees
60
Country
Switzerland
ISIN
CH1242303498
WKN
000A3D8QG

Listings

STU
DE
CR5.STU
XNAS
US
OCS
XNAS
US
OCSAW
F
DE
CR5.F

0 Comments

Share your thoughts

FAQ

What is Oculis stock price today?▼
The current price of OCS is $12.97 USD — it has increased by +0.08% in the past 24 hours. Watch Oculis stock price performance more closely on the chart.
What is Oculis stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Oculis stocks are traded under the ticker OCS.
Is Oculis stock price growing?▼
OCS stock has fallen by -1.29% compared to the previous week, the month change is a +17.7% rise, over the last year Oculis has showed a -25.14% decrease.
What is Oculis market cap?▼
Today Oculis has the market capitalization of 720.2M
When is the next Oculis earnings date?▼
Oculis is going to release the next earnings report on November 05, 2026.
What were Oculis earnings last quarter?▼
OCS earnings for the last quarter are -0.2 USD per share, whereas the estimation was -0.48 USD resulting in a +58.76% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Oculis revenue for the last year?▼
Oculis revenue for the last year amounts to 0 USD.
What is Oculis net income for the last year?▼
OCS net income for the last year is -120.39M USD.
How many employees does Oculis have?▼
As of August 27, 2026, the company has 60 employees.
In which sector is Oculis located?▼
Oculis operates in the Health & Wellness sector.
When did Oculis complete a stock split?▼
Oculis has not had any recent stock splits.
Where is Oculis headquartered?▼
Oculis is headquartered in Zug, Switzerland.